|By mouth (capsules)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||199.31 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Cevimeline (trade name Evoxac) is a synthetic analog of the natural alkaloid muscarine with a particular agonistic effect on M1 and M3 receptors. It is used in the treatment of dry mouth and Sjögren's syndrome.
Cevimeline is used in the treatment of xerostomia (dry mouth), and Sjögren's syndrome. It increases the production of saliva.
Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.
Contraindications include asthma and angle closure glaucoma.
Cevimeline is a cholinergic agonist. It has a particular effect on M1 and M3 receptors. By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.